This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Definitive Healthcare Corp. (DH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 150% and 5.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 4th
by Zacks Equity Research
Teaser: AMRC, DH and AAON have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2025.
Definitive Healthcare Corp. (DH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 14.29% and 3.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Magnite (MGNI) Matches Q4 Earnings Estimates
by Zacks Equity Research
Magnite (MGNI) delivered earnings and revenue surprises of 0% and 2.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Intuit Q2 Earnings Surpass Estimates, Revenues Increase Y/Y
by Zacks Equity Research
INTU's fiscal second-quarter results surpass expectations, reflecting strength in the Global Business Solutions segment.
Oddity Tech (ODD) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Oddity Tech (ODD) delivered earnings and revenue surprises of 53.85% and 3.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DH or FFIV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. FFIV: Which Stock Is the Better Value Option?
Unity Software Inc. (U) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Unity Software (U) delivered earnings and revenue surprises of 14.29% and 5.87%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DH vs. FFIV: Which Stock Is the Better Value Option?
by Zacks Equity Research
DH vs. FFIV: Which Stock Is the Better Value Option?
Definitive Healthcare (DH) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Definitive Healthcare (DH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Definitive Healthcare (DH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Definitive Healthcare (DH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -5.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Definitive Healthcare (DH)
by Zacks Equity Research
Definitive Healthcare (DH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
DH or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
DH vs. PRVA: Which Stock Is the Better Value Option?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
DH vs. PRVA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
Surging Earnings Estimates Signal Upside for Definitive Healthcare (DH) Stock
by Zacks Equity Research
Definitive Healthcare (DH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
DH or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 25% and 1.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nyxoah (NYXH) delivered earnings and revenue surprises of -47.83% and 17.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DH vs. GEHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
DH vs. GEHC: Which Stock Is the Better Value Option?
Implied Volatility Surging for Definitive Healthcare (DH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Definitive Healthcare (DH) stock based on the movements in the options market lately.
Definitive Healthcare Corp. (DH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DH or PRVA: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DH vs. PRVA: Which Stock Is the Better Value Option?
Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Definitive Healthcare (DH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.